ArticleClinical and translational science2025
Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Head-to-head comparison of fasting-insulin-based versus non-insulin-based insulin resistance surrogates for predicting all-cause and cardiovascular mortality in hypertensive adults across the glycemic continuum: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Elevated stress hyperglycemia ratio predicts intensive care unit admission after surgery for gastrointestinal tumors: an INSPIRE database analysis.Frontiers in medicine · 2026Article
- Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostic assessment of chronic thromboembolic pulmonary hypertension (CTEPH) remains challenging. Stress hyperglycemia, a condition where glucose metabolism is regulated during stress, has been regarded as an indicator of acute hyperglycemia. The stress hyperglycemia ratio (SHR) serves as a more precise marker for this state. This research intended to investigate the prognostic function of SHR in CTEPH, as its link to poor outcomes is uncertain. Clinical deterioration events were the primary endpoint. LASSO regression was utilized for variable selection and dimensionality reduction to identify key features and mitigate overfitting. Kaplan-Meier analysis, multivariable Cox regression, and restricted cubic splines were primarily used to investigate the link between SHR and adverse clinical outcomes. Internal validation was performed using bootstrap resampling. Sensitivity analysis was performed to assess the robustness of the findings. The study included a sum of 451 patients with CTEPH; over a median follow-up of 21 months, 89 (19.7%) patients encountered adverse outcomes. Kaplan-Meier analysis indicated that patients having elevated SHR levels exhibited a markedly higher overall incidence of adverse events. Restricted cubic spline analysis showed a linear relationship between SHR and adverse events. Multivariable Cox regression analysis indicated that higher SHR independently predicts adverse outcomes, whether treated as continuous (hazard ratio, 1.541; 95% confidence interval, 1.252-1.896, p < 0.001) or categorical (hazard ratio, 2.419; 95% confidence interval, 1.268-4.616, p = 0.007). Internal validation demonstrated that the original C-index was 0.693, with a bias-corrected C-index of 0.675 after bootstrap validation. In patients with CTEPH, higher SHR is independently associated with clinical worsening. The prognostic significance of SHR remained robust across internal validation and multiple sensitivity analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.